Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 14/20 | 0.50 |
| ▸ | CALCR | P30988 | 14/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12337799 | 0.92 | RAMP3 (0.46) | RAMP3CALCRIL23RAPLNRKDM1A | |
| SCHEMBL16351203 | 0.91 | RAMP3 (0.48) | RAMP3CALCRIL23RAPLNRNMUR2 | |
| SCHEMBL12337845 | 0.91 | RAMP3 (0.46) | RAMP3CALCRIL23RAPLNRKDM1A | |
| SCHEMBL16351204 | 0.87 | RAMP3 (0.46) | RAMP3CALCRIL23R | |
| SCHEMBL12339085 | 0.87 | RAMP3 (0.46) | RAMP3CALCRIL23R | |
| SCHEMBL12314876 | 0.85 | RAMP3 (0.47) | RAMP3CALCRIL23R | |
| SCHEMBL13084645 | 0.85 | RAMP3 (0.47) | RAMP3CALCRIL23R | |
| SCHEMBL12314880 | 0.85 | RAMP3 (0.47) | RAMP3CALCRIL23R | |
| SCHEMBL13084700 | 0.85 | RAMP3 (0.47) | RAMP3CALCRIL23R | |
| SCHEMBL16351202 | 0.84 | OPRM1 (0.49) | RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | RAMP3 1333/4885CALCR 928/4885IL23R 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.